Ce produit n'est pas destiné à diagnostiquer, traiter, guérir ou prévenir toute maladie. Ces déclarations n'ont pas été évaluées par la Food and Drug Administration.
Ces informations sont fournies à titre éducatif uniquement et ne remplacent pas un avis médical professionnel, un diagnostic ou un traitement. Consultez toujours votre professionnel de santé avant d'utiliser des plantes, surtout si vous êtes enceinte, allaitez, prenez des médicaments ou avez une condition médicale.
PD
Not CommonRésumée par IA
Pau Darco Intérieur
Tabebuia impetiginosa
Infections et candidose dans la tradition sud-américaine
How does Pau D'Arco work as an antifungal and antimicrobial?
Pau D'Arco works primarily through active compounds called lapachol and beta-lapachone. These naphthoquinones disrupt the electron transport chain in microbial cells, effectively interfering with their ability to generate energy. This mechanism inhibits the growth of various fungi, bacteria, and viruses. While laboratory studies (Evidence Level C) demonstrate these antimicrobial properties, clinical trials confirming the specific mechanism of action in humans are currently limited.
Does Pau D'Arco interact with blood thinners like Warfarin?
Yes, Pau D'Arco has significant anticoagulant properties and can interact with blood-thinning medications. The compound lapachol inhibits blood clotting, which may potentiate the effects of anticoagulant drugs like warfarin or antiplatelet medications like aspirin. This combination increases the risk of bleeding and bruising. Patients taking anticoagulants should avoid Pau D'Arco unless specifically monitored by a healthcare provider (Evidence Level C/D).
What is the recommended dosage for Pau D'Arco inner bark?
Traditional adult dosage involves preparing a decoction using 15-20 grams of dried inner bark, simmered in water for 10-15 minutes, consumed up to three times daily. For standardized extracts, a common dosage is 300 mg taken three times daily. It is crucial to use the inner bark specifically, as other parts of the tree contain lower concentrations of active compounds. Dosage recommendations are based on traditional use and pharmacological data (Evidence Level C).
Is Pau D'Arco safe to take during pregnancy?
No, Pau D'Arco is considered unsafe during pregnancy and breastfeeding. The active compound lapachol has demonstrated potential toxic effects and uterine stimulant activity in animal studies, which could lead to miscarriage or fetal harm. Historical texts and modern herbalists contraindicate its use for expectant mothers. Women who are pregnant or nursing should avoid Pau D'Arco supplements and teas entirely (Evidence Level D/Traditional).
Can Pau D'Arco be used to treat Candida overgrowth?
Pau D'Arco is traditionally used to treat Candida yeast infections due to its antifungal properties. In vitro studies show that beta-lapachone inhibits the growth of Candida species by disrupting cell wall formation. While these results are promising, high-quality human clinical trials are lacking (Evidence Level C). It is often used as a complementary tea or extract, but should not replace standard antifungal medications without professional guidance.
Fiche d'information compilée à partir de PubMed
Cette fiche a été compilée à partir de résumés PubMed (NIH) avec l'assistance d'une IA. Chaque affirmation factuelle est citée par un article PubMed réel (voir la liste des sources). Elle n'a pas encore été révisée par un humain — confirmez auprès d'un professionnel de santé avant utilisation.
Compilé à partir de 30 articles PubMed · modèle : gemma4:31b
Résumé
Pau Darco (Tabebuia impetiginosa), also known as Taheebo, is a South American canopy tree whose inner bark is used in traditional medicine for various infections and inflammatory conditions [PMID:18992801, PMID:32962180].
Contexte
Tabebuia impetiginosa is a plant native to the Amazon rainforest and other regions of Latin America [PMID:32962180]. It is often referred to as Red Lapacho or Taheebo [PMID:18992801, PMID:28927490].
Usages traditionnels
Traditionally, a decoction of the inner bark is used to treat bacterial and fungal infections, fever, syphilis, malaria, trypanosomiasis, stomach and bladder disorders, and skin diseases [PMID:18992801, PMID:32962180]. It has also been used as a general tonic, immunostimulant, adaptogen, and for motor disorders [PMID:35240121], as well as for memory enhancement and central nervous system stimulation [PMID:38705428].
Composés actifs
Identified compounds include naphthoquinones such as lapachol, $\beta$-lapachone, and $\alpha$-lapachone [PMID:28586252, PMID:21637695]. Other constituents include 2-(hydroxymethyl)anthraquinone, anthraquinone-2-carboxylic acid [PMID:16359837], veratric acid [PMID:28927490], cyclopentene dialdehydes [PMID:10820794], and various iridoid, phenylethanoid, phenolic, and lignan glycosides [PMID:15721952, PMID:15280007, PMID:16394542]. Volatile constituents include 4-methoxybenzaldehyde, 4-methoxyphenol, elemicin, trans-anethole, and 4-methoxybenzyl alcohol [PMID:12502424].
Mécanisme d'action
The herb may suppress the production of prostaglandin E(2) and nitric oxide (NO) by blocking the mRNA expression of COX-II and iNOS through the interruption of ERK activation [PMID:18634864]. Lapachol and $\beta$-lapachone may induce apoptosis by generating oxygen-reactive species and inhibiting topoisomerases I and II [PMID:21637695]. Inner bark extracts have also been shown to inhibit platelet aggregation and vascular smooth muscle cell proliferation by suppressing arachidonic acid liberation and ERK1/2 MAPK activation [PMID:16766151].
Preuves cliniques
Preuve BPrimary Dysmenorrhea
A single-arm, open-label trial of 1050 mg/day of encapsulated Tabebuia avellanedae in 12 women found the treatment to be safe and tolerable [PMID:36960315].
Preuve DHelicobacter pylori
In vitro assays showed that 2-(hydroxymethyl)anthraquinone exhibited strong growth-inhibiting activity against H. pylori [PMID:16359837].
Preuve DCancer (Cell Lines)
Extracts showed cytotoxicity in human tumor cell lines (MCF-7, NCI-H460, HeLa, and HepG2) [PMID:26703544] and dose-dependent growth inhibition and apoptosis in ER+ MCF-7 breast cancer cells [PMID:19578798].
Preuve DInflammation/Pain
Animal models demonstrated significant anti-nociceptive and anti-inflammatory effects at 200 mg/kg [PMID:22888300, PMID:22825254].
Preuve DPostprandial Triglycerides
Bark extract significantly delayed the postprandial increase of plasma triglycerides in rats by inhibiting pancreatic lipase [PMID:22431070].
Preuve D
Sécurité et effets indésirables
A clinical trial for dysmenorrhea reported the herb was safe and tolerable [PMID:36960315]. However, a study on Wistar rats found that flower extract (not bark) caused a significant increase in DNA damage in blood and liver cells at doses of 300 and 500 mg/kg [PMID:22888300].
Synthèse des preuves
The evidence consists primarily of in vitro studies and animal models (Level D), with one small, open-label clinical trial (Level B) focusing on safety and tolerability. There is a lack of large-scale RCTs or systematic reviews to confirm clinical efficacy in humans.
Sources PubMed
1.PMID: 18992801 (2009) — Red Lapacho (Tabebuia impetiginosa)--a global ethnopharmacological commodity? · Journal of ethnopharmacology
2.PMID: 32962180 (2020) — Tabebuia impetiginosa: A Comprehensive Review on Traditional Uses, Phytochemistry, and Immunopharmacological Properties. · Molecules (Basel, Switzerland)
4.PMID: 35240121 (2022) — Antiparkinsonian activity of Tabebuia impetiginosa bark and biochemical analysis of dopamine in rat brain homogenates. · Annales pharmaceutiques francaises
5.PMID: 34361435 (2021) — Evaluation of the Mechanical and Biocidal Properties of Lapacho from Tabebuia Plant as a Biocomposite Material. · Materials (Basel, Switzerland)
Sources gouvernementales
Aucune monographie gouvernementale directe n'est disponible pour cette plante. Le contenu ci-dessous est généré par IA et n'a pas été vérifié par rapport à une source gouvernementale faisant autorité. Utilisez les liens de recherche pour consulter les sources officielles avant de vous fier à ces informations.
Experimental methods explored antiparkinsonian activity using aqueous bark extracts in rats [PMID:35240121].
6.PMID: 16359837 (2006) — Antibacterial activity of Tabebuia impetiginosa Martius ex DC (Taheebo) against Helicobacter pylori. · Journal of ethnopharmacology
7.PMID: 32875965 (2022) — Isolation of endophytic bacteria from the medicinal, forestal and ornamental tree Handroanthus impetiginosus. · Environmental technology
8.PMID: 22431070 (2012) — Lapacho tea (Tabebuia impetiginosa) extract inhibits pancreatic lipase and delays postprandial triglyceride increase in rats. · Phytotherapy research : PTR
9.PMID: 26703544 (2015) — Bioactive Properties of Tabebuia impetiginosa-Based Phytopreparations and Phytoformulations: A Comparison between Extracts and Dietary Supplements. · Molecules (Basel, Switzerland)
10.PMID: 28586252 (2017) — Lapachol and lapachone analogs: a journey of two decades of patent research(1997-2016). · Expert opinion on therapeutic patents
11.PMID: 15721952 (2005) — Further constituents from the bark of Tabebuia impetiginosa. · Phytochemistry
12.PMID: 18634864 (2008) — In vitro and in vivo anti-inflammatory effects of taheebo, a water extract from the inner bark of Tabebuia avellanedae. · Journal of ethnopharmacology
13.PMID: 15280007 (2004) — Constituents from the bark of Tabebuia impetiginosa. · Phytochemistry
14.PMID: 16394542 (2006) — Constituents from the bark of Tabebuia impetiginosa. · Chemical & pharmaceutical bulletin
15.PMID: 28927490 (2018) — Development and Validation of an Analytical Method Readily Applicable for Quality Control of Tabebuia impetiginosa (Taheebo) Ethanolic Extract. · Journal of AOAC International
16.PMID: 21637695 (2009) — Modulatory effects of Tabebuia impetiginosa (Lamiales, Bignoniaceae) on doxorubicin-induced somatic mutation and recombination in Drosophila melanogaster. · Genetics and molecular biology
17.PMID: 38705428 (2024) — LC-qTOF-MS/MS phytochemical profiling of Tabebuia impetiginosa (Mart. Ex DC.) Standl. leaf and assessment of its neuroprotective potential in rats. · Journal of ethnopharmacology
18.PMID: 19578798 (2009) — Growth inhibition of estrogen receptor positive human breast cancer cells by Taheebo from the inner bark of Tabebuia avellandae tree. · International journal of molecular medicine
19.PMID: 12502424 (2003) — Antioxidant activity and characterization of volatile constituents of Taheebo (Tabebuia impetiginosa Martius ex DC). · Journal of agricultural and food chemistry
20.PMID: 27539320 (2016) — The anti-obesity effect of Taheebo (Tabebuia avellanedae Lorentz ex Griseb) extract in ovariectomized mice and the identification of a potential anti-obesity compound. · Biochemical and biophysical research communications
21.PMID: 22825254 (2012) — Analgesic and anti-inflammatory effects in animal models of an ethanolic extract of Taheebo, the inner bark of Tabebuia avellanedae. · Molecular medicine reports
22.PMID: 15067185 (2004) — [Suppression of glucose absorption by various health teas in rats]. · Yakugaku zasshi : Journal of the Pharmaceutical Society of Japan
23.PMID: 15713033 (2005) — Selective growth-inhibiting effects of compounds identified in Tabebuia impetiginosa inner bark on human intestinal bacteria. · Journal of agricultural and food chemistry
24.PMID: 36960315 (2022) — Safety and tolerability of Pau d' Arco (Tabebuia avellanedae) for primary dysmenorrhea: A single-arm, open-label trial on adults ages 18-45. · Advances in integrative medicine
25.PMID: 31582051 (2019) — A polysaccharide fraction from "ipê-roxo" (Handroanthus heptaphyllus) leaves with gastroprotective activity. · Carbohydrate polymers
26.PMID: 28877696 (2017) — Oral administration of taheebo (Tabebuia avellanedae Lorentz ex Griseb.) water extract prevents DSS-induced colitis in mice by up-regulating type II T helper immune responses. · BMC complementary and alternative medicine
27.PMID: 16766151 (2006) — Inhibitory effects of Tabebuia impetiginosa inner bark extract on platelet aggregation and vascular smooth muscle cell proliferation through suppressions of arachidonic acid liberation and ERK1/2 MAPK activation. · Journal of ethnopharmacology
28.PMID: 22888300 (2012) — Genotoxic effects of Tabebuia impetiginosa (Mart. Ex DC.) Standl. (Lamiales, Bignoniaceae) extract in Wistar rats. · Genetics and molecular biology
29.PMID: 33620676 (2021) — Grzybowski's Generalized Eruptive Keratoacanthomas in a Patient with Terminal Kidney Disease-An Unmet Medical Need Equally Ameliorated by Topical Imiquimod Cream and Lapacho Tea Wraps: A Case Report. · Dermatology and therapy
30.PMID: 30279507 (2018) — Single Dose Administration of Taheebo Polyphenol Enhances Endurance Capacity in Mice. · Scientific reports